Ann‐Sofie Månsson
YOU?
Author Swipe
Decoding of the surfaceome and endocytome in primary glioblastoma cells identifies potential target antigens in the hypoxic tumor niche Open
Immunotherapies with antibody–drug-conjugates (ADC) and CAR-T cells, targeted at tumor surface antigens (surfaceome), currently revolutionize clinical oncology. However, target identification warrants a better understanding of the surfaceo…
View article: Supplementary Fig. 5 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Supplementary Fig. 5 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
Figure S5. Flow chart of the selection process of patients.
View article: Supplementary Fig. 4 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Supplementary Fig. 4 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
S4. Hypoxia induces resistance to Abraxane in SKBR3 cells.
View article: Supplementary Fig. 5 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Supplementary Fig. 5 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
Figure S5. Flow chart of the selection process of patients.
View article: Supplementary Fig. 7 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Supplementary Fig. 7 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
Figure S7. Histology of primary breast cancer tissue.
View article: Supplementary Fig. 1 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Supplementary Fig. 1 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
S1. Caspase induction in SKBR3 cells pre-incubated for 20 h in normoxia or hypoxia and treated with T-DM1 was measured using the Caspase-Glo 3/7 assay kit and the results are shown as mean luminescence (measured in relative light units [RL…
View article: Supplementary Table 1 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Supplementary Table 1 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
Supplementary Table 1. Patient and tumor characteristics in relation to tumor-specific cytoplasmic intensity of CAV1
View article: Supplementary Table 1 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Supplementary Table 1 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
Supplementary Table 1. Patient and tumor characteristics in relation to tumor-specific cytoplasmic intensity of CAV1
View article: Supplementary Fig. 1 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Supplementary Fig. 1 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
S1. Caspase induction in SKBR3 cells pre-incubated for 20 h in normoxia or hypoxia and treated with T-DM1 was measured using the Caspase-Glo 3/7 assay kit and the results are shown as mean luminescence (measured in relative light units [RL…
View article: Supplementary Fig. 7 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Supplementary Fig. 7 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
Figure S7. Histology of primary breast cancer tissue.
View article: Supplementary Fig. 6 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Supplementary Fig. 6 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
S6. CAV1 is expressed in the cytoplasm of invasive tumor cells in primary breast cancer tissue.
View article: Data from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Data from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
The antibody–drug conjugate trastuzumab-emtansine (T-DM1) offers an additional treatment option for patients with HER2-amplified tumors. However, primary and acquired resistance is a limiting factor in a significant subset of patients. Hyp…
View article: Supplementary Fig. 3 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Supplementary Fig. 3 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
S3. Cytotoxicity of T-DM1 catabolites is not altered by hypoxia. Dose response curves showing sensitivity of normoxic or hypoxic SKBR3 and BT474 cells treated with T-DM1 catabolites, DM1 (A, D), MCC-DM1 (B, E), and LMCC-DM1 (C, F) for 72 h…
View article: Supplementary Fig. 2 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Supplementary Fig. 2 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
S2. Phospho-kinase antibody array analyses of normoxia (a) or hypoxia (b) level expressed as normalized to reference standard.
View article: Supplementary Fig. 2 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Supplementary Fig. 2 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
S2. Phospho-kinase antibody array analyses of normoxia (a) or hypoxia (b) level expressed as normalized to reference standard.
View article: Supplementary Fig. 4 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Supplementary Fig. 4 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
S4. Hypoxia induces resistance to Abraxane in SKBR3 cells.
View article: Supplementary Fig. 3 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Supplementary Fig. 3 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
S3. Cytotoxicity of T-DM1 catabolites is not altered by hypoxia. Dose response curves showing sensitivity of normoxic or hypoxic SKBR3 and BT474 cells treated with T-DM1 catabolites, DM1 (A, D), MCC-DM1 (B, E), and LMCC-DM1 (C, F) for 72 h…
View article: Supplementary Fig. 6 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Supplementary Fig. 6 from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
S6. CAV1 is expressed in the cytoplasm of invasive tumor cells in primary breast cancer tissue.
View article: Data from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1
Data from Hypoxia Attenuates Trastuzumab Uptake and Trastuzumab-Emtansine (T-DM1) Cytotoxicity through Redistribution of Phosphorylated Caveolin-1 Open
The antibody–drug conjugate trastuzumab-emtansine (T-DM1) offers an additional treatment option for patients with HER2-amplified tumors. However, primary and acquired resistance is a limiting factor in a significant subset of patients. Hyp…
Landscape of surfaceome and endocytome in human glioma is divergent and depends on cellular spatial organization Open
Significance Cancer immunotherapies, including checkpoint inhibitor blocking antibodies and antibody drug conjugates, currently revolutionize cancer treatment. However, a remaining challenge is the identification of tumor surfaceome (TS) t…
Tumor antigen glycosaminoglycan modification regulates antibody-drug conjugate delivery and cytotoxicity Open
Aggressive cancers are characterized by hypoxia, which is a key driver of tumor development and treatment resistance. Proteins specifically expressed in the hypoxic tumor microenvironment thus represent interesting candidates for targeted …